# Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

> **NCT02520245** · PHASE1 · WITHDRAWN · sponsor: **Regeneron Pharmaceuticals**

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** REGN2810

## Key facts

- **NCT ID:** NCT02520245
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-08
- **Primary completion:** 2023-11
- **Final completion:** 2023-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02520245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02520245, "Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02520245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*